Key takeaways:

Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain patients with prostate cancer.

Patients with BRCA1/2 mutations had a 48% risk reduction.

Perspectives from Bradley McGregor, MD; Nabil Adra, MD

CHICAGO — Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic castration-sensitive prostate cancer with homologous recombination repair gene alterations.

Findings of the AMPLITUDE trial, presented at ASCO Annual Meeting, build on previous data from the MAGNITUDE trial, which led to the approval of niraparib with abiraterone acetate plus prednisone for patients with homologous recombination repair-altered metastatic castration-resistant prostate cancer (mCRPC

See Full Page